To OTC Journal Members:

Correction from Weekend Edition - My new price target for Apple Computer (NASDAQ: AAPL) is now $225 - not $125 which was a typo I didn't catch.
 

eFoodSafety (OTC BB: EFSF): Ending The Silence With Style

They say silence can be deafening, and anyone listening to EFSF for the past four months has completely lost their hearing as far as this stock is concerned. Here's the deal - EFSF was very vocal in the first half of the year about new product introductions. Cinnechol was supposed to be flying off the shelves by now. Pureffect was supposed to be featured on TV, and Oraphyte was supposed to be taking the agro biotech world by storm.

Here's the bad news - aside from moderate sales of Cinnergen, EFSF hasn't delivered on any of these promised product roll outs. Here's the good news - the delays are already reflected in the price of the stock, so a resumption of activity should lead the stock to higher levels.

I get more questions about the status of EFSF products than any other single subject I cover. Probably because there were very high hopes for these products, and investors are becoming impatient. I can't blame them. Activity has been long overdue, and it should start picking up now.

For everyone to read, here's an update on what I know about the status of EFSF's"Big 4" product line up:

• Cinnergen: EFSF's natural sugar metabolizing liquid is great for diabetics and those wishing to metabolize carbs more efficiently. Sales are improving, although not hitting the levels the company had hoped for. Big campaign planned for November, which is National Diabetes Month, and look for it to be added at many more retail locations with big chains.
• PurEffect: EFSF's eagerly anticipated acne treatment product is going to go head to head with ProActive, the unchallenged leader in the field to date. Celebrity endorsements are coming via Carmen Elektra and Maria Menundos, and other celebrities to be named. It will be sold by infomercial. Filming has been completed, and the infomercial is in the editing stage. There have been no media buys yet, but marketing is supposed to commence some time after the first of the year.
• Oraphyte: The natural answer nematodes, the critters that cause billions in crop damage every year. The product was originally tested by the USDA, but potential multi national marketing partners want University studies, which are currently underway. There is still lots of interest from the big boys, but nothing is going to happen until studies are completed.
• Cinnechol: EFSF's natural cholesterol fighting product is completed and ready for market. Like Cinnergen, recent clinical studies are impressive and prove out the product's effectiveness. EFSF is seeking a strategic marketing partner right now.

Enter The Immune Bar

I've gotten a lot of questions on this product, and I really didn't know much about it until today's news. This is EFSF's new immune bar. It's a healthy energy bar fully of anti oxidants and other good stuff designed to enhance your immune system's strength.

You are getting a first look at the packaging. Today, just after the market closed, EFSF announced the product is ready for market, and I expect news of how, where, and when in the near future.

I haven't tried the product yet, but I do have a shipment of all three versions on the way, and will have a chance to try them by the weekend.

EFSF has clearly bit mute of late, but this product introduction should probably get the stock headed back up. It also will probably mark the beginning of a robust news cycle and a fair amount of corporate activity. Financially, I believe the company is in very good shape considering the limited sales volume. They have cash, no debt, and no toxic financings. All ingredients for stock price appreciation when there's corporate achievement.

Technically, there's not much to say about the stock other than "oversold". This chart goes back to my initial coverage on the company in January at $.18 per share. This is a weekly chart - it shows the price movement on a week by week basis.

As you can see, the stock did very well through the April time frame, and has been grinding lower now for about 6 months. Volume is lighter, and the stock appears to have found a bottom.

Breaking below the $.30 line was not good, but it happened. It is what it is. Time to rebuild.

At least it didn't go back as low as our starting point. News of the introduction of the Immune Bar should energize the market once again. This company has a loyal shareholder base who believe in the long term prospects for their products.

Since it's oversold and the volume is low, it could rebound quite easily. Perhaps it will find $.30 again in short order, which would be welcome relief for patient investors.

Here is the complete text of today's news release for your review:
 

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Go Here to view our compensation on every company we have ever covered, or visit the following web address: http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of $30,000 cash and 1 million newly issued restricted shares by eFoodSafety for coverage of the company.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services.

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $310,0000 in the Longview Fund (“the Longview Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner. No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Longview Fund. Longview ocassoinally refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter. Longview may or may not own shares in the companies that it so refers to MarketByte. MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Longview owns any shares in the companies that it refers to MarketByte LLC. The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies.

The profiles, critiques, and other editorial content of the OTCJournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF OTCJournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID: Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. MarketByte LLC's mailing address is 4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.